Life sciences firm Agilent beats quarterly estimates on instrument demand
The company also raised its annual revenue forecast to be between $6.73 billion and $6.81 billion, compared to its prior expectations of $6.68 billion to $6.76 billion. It maintained its fiscal 2025 adjusted profit forecast at $5.54 to $5.61 per share.
Life sciences firms like Agilent have seen weak order levels in the past two years due to reduced spending from biotech clients, and investors have expressed concerns that the difficulties, initially expected to ease this year, may persist due to policy uncertainties from the Trump administration.
"The Agilent team delivered strong second-quarter results in a highly dynamic market environment,' said President and CEO Padraig McDonnell.
Agilent, which was spun off from pre-split Hewlett-Packard in 2000, reported second-quarter sales of $1.67 billion, above the analysts' estimate of $1.63 billion, according to data compiled by LSEG.
Sales in its life sciences and diagnostics segment were at $654 million, beating the estimate of $639.4 million, while revenue from its CrossLab unit, which offers products and services for laboratory management, came in at $713 million, above the estimate of $645.1 million.
On an adjusted basis, the California-based company reported a profit of $1.31 per share, beating the estimate of $1.26 per share.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
16 minutes ago
- Daily Mail
Beach City abandons 10,000 homes for F1-style race track development
Locals in a popular New Jersey beach city are enraged after it ditched plans to build 10,000 new homes for a 'dumb' and 'desperate' $3.4 billion F1-style racetrack. Atlantic City government officials have moved forward with the redevelopment of Bader Field, a shuttered airport about an hour outside of Philadelphia, after plans for the new racetrack were officially approved on July 16. The idea to take over the abandoned city-owned airport, which shut down in 2006, first started in 2022 when Bart Blatstein, the CEO of Tower Investments, Inc. and owner of Showboat Atlantic City, said his company and Atlantic City would collaborate to create a massive residential community. The proposed $3 billion development, dubbed 'Casa Mar,' was set to be built on 140 acres with 10,000 residential units, 20 acres of trails, amenities and parks and 400,000 square-feet of retail and office space - but that plan has since been wiped. Instead, a 2.5-mile racetrack, headed by real estate development company Deem Enterprises, will take its place. The massive raceway, said to be a 'game changer' by Atlantic City Mayor Marty Small Sr. (pictured), is expected to take six to nine years to complete. It will be surrounded by retail businesses and condominiums in the community that is home to beaches, a bustling boardwalk and casinos. 'We're more confident than ever that we have the funds, Small Sr., an Atlantic City native who has been in office since 2019, told NJ Advance Media. [DEEM] has been vetted, and just getting a $3.4-plus billion project on the ratable base is a complete game changer.' While the mayor, who was embroiled in a child abuse scandal involving his wife and daughter last year, and other government officials are thrilled about the new plan, Atlantic City locals are not happy with it. 'Atlantic City leadership is so desperate that they will support any development offer no matter how stupid it is,' a Facebook user wrote. Another said: 'What a joke! Want to really do something with the land? Dig canals and sell off lots and watch the ratepayers flood in!' 'Building that into a racetrack has to be the dumbest idea in the world,' someone else posted. Blatstein told the outlet three years ago that he saw room for growth in the beach city after realizing that other Garden State beach towns have booming populations compared to Atlantic City. 'So what really is needed here is a new plan, a new way of living, a new opportunity for people to come to Atlantic City,' Blatstein said. DEEM Enterprises, a Los Angeles and Atlantic City-based company, first announced the proposal in February of that year. The company has a tentative deal with the city to sell the vacant airfield for $100 million in exchange the real estate developer would donate $15 million for a community center. 'We don't have a recreation center of our town,' Small Sr. explained. 'We use the schools and different things like that.' Daily Mail contacted Mayor Small Sr. and DEEM Enterprises for comment.
The Independent
18 minutes ago
- The Independent
Ham salad brands recalled over listeria contamination fears
The U.S. Department of Agriculture's Food Safety and Inspection Service issued a public health warning for Reser's Fine Foods Ham Salad and Molly's Kitchen Ham Salad over listeria contamination fears. According to a press release from the agency, the possible contamination was discovered when a Reser's, based in Topeka, Kansas, was found to have used a breadcrumb product that was already subject to a Listeria monocytogenes recall. There have been no reports of illness among consumers due to contamination. The agency advises anybody who has consumed the products to seek medical help immediately. The specific warning is for 12-ounce plastic tubs of 'Reser's Fine Foods Ham Salad' with expiration dates of 09/01/2025 and 5-pound plastic tubs of 'Molly's Kitchen Ham Salad' with expiration dates of 08/31/2025. The FSIS warning raises concerns that retailers and consumers may have the product in their refrigerators and freezers. Customers are asked to be mindful and refrain from eating the named products. In May, a listeria outbreak linked to ready-to-eat sandwiches and snacks has sickened at least 10 people in the U.S. A producer is voluntarily recalling dozens of products sold to retail stores, hospitals, hotels, airports, and airlines, federal officials said. Listeria poisoning is caused by a particularly resilient type of bacteria that can survive and grow even during refrigeration. About 1,600 people are infected with it — and 260 die each year in the U.S., according to the CDC. Listeria bacteria thrive in moist environments, including soil, water, and decaying vegetation, and are carried by some animals. The hardy germs are typically spread when food is harvested, processed, transported or stored in places that are contaminated with the bacteria. When bacteria enter a food processing plant, they can be difficult to eradicate. Foods contaminated with the bacteria can cause people to become ill. Symptoms can be mild and include fever, muscle aches, nausea, vomiting, and diarrhea. More serious illnesses can include headache, stiff neck, confusion, loss of balance, and convulsions. Listeria poisoning is challenging because symptoms can develop quickly, within a few hours or days after consuming contaminated food. However, they can also take weeks or up to three months to appear. Those most vulnerable to getting sick include the very young, people older than 65, and those with weakened immune systems or who are pregnant. Listeria can survive and grow in refrigerated food. It can be killed by heating foods to 'steaming hot,' or 165 degrees Fahrenheit (74 degrees Celsius), the CDC says. But that's not always possible — or palatable—for foods that are made to be eaten cold. Because Listeria can survive under refrigeration, it's essential to clean and sanitize any surfaces, including refrigerator drawers and shelves, that may have come into contact with the products.
The Independent
18 minutes ago
- The Independent
Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Novo Nordisk's weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors. Since the US Food and Drug Administration (FDA) implemented a ban on 'compounded' versions of Wegovy on 22 May, new prescriptions for the drug have risen by approximately 33 per cent. This culminated in 181,200 new prescriptions in the week ending 18 July, according to IQVIA data shared with Reuters by industry analysts. The overall increase in Wegovy prescriptions is also narrowing the market lead held by Eli Lilly and Co's rival drug, Zepbound. While Zepbound prescriptions outpaced Wegovy by nearly 175,000 in the US during the week ending 23 May, this gap had reduced to around 133,000 by 18 July. Early signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's growth. And then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 peak. Jorgensen said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August 6. That leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to deliver. She has an "overweight" rating on Novo's shares. "We thought this trajectory change (in new prescriptions) would get the shares moving, but not so far," Berenberg analyst Kerry Holford told Reuters. "I suspect investors are now waiting for the (second quarter) update - will they/won't they trim guidance range? I think they will trim the top." Berenberg has a "hold" rating on Novo. Novo did not respond to a request for comment. Investors and analysts note that the IQVIA prescription data is incomplete, because it does not capture sales of Wegovy through the company's direct-to-consumer platform, NovoCare, launched in March. They estimate the channel is still a small slice of overall Wegovy volume. "We would hope to see strong growth from the NovoCare channel but are cognizant that this may come at initially lower prices" due to discount offers, said Marcus Morris-Eyton, a portfolio manager at Alliance Bernstein, whose fund holds Novo shares. "Sentiment towards Novo Nordisk is currently exceptionally weak, but given low expectations, the low valuation and hopefully accelerating prescription data in (the second half of 2025) we believe the market is underestimating Novo's long term growth potential," he said. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the U.S. in 2021. But supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under U.S. law when drugs are in shortage. Investor sentiment on Novo soured after the company lost ground to U.S. rival Eli Lilly, which launched Zepbound in late 2023. Capturing more of the patients who had turned to compounded drugs is key to meeting targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health. Analysts at Berenberg and UBS are sceptical these moves will provide enough momentum and expect that Novo will reduce or narrow its full-year guidance ranges, according to research notes. TD Cowen said the outcome was hard to predict due to limited visibility on NovoCare. Bank of America and Guggenheim said they did not expect another guidance cut and Barclays said it was unlikely. ($1 = 0.8513 euros)
